Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReDos HCC: Regorafenib Dose Optimization
NCT04476329Phase 2Terminated
- Sponsor
- SC Liver Research Consortium
- Start
- Jan 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by SC Liver Research Consortium. Started Jan 2021; status: terminated.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04476329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04476329.